Anne Lesage Acquires Shares of Pharvaris N.V.
Pharvaris N.V.'s Chief Early Development, Anne Lesage, purchased 2,300 shares.
Key Points
- Anne Lesage, Chief Early Development at Pharvaris N.V., purchased 2,300 shares at an average price of $4.73 on June 25, 2026.
- Shares of Pharvaris N.V. traded near $34.01 on Tuesday, with a market cap of $2.38 billion and a 52-week range of $16.72 to $35.33.
- Morgan Stanley maintained a buy rating on Pharvaris with a $46 target on June 25, 2026, amid strong institutional interest.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Anne Lesage, the Chief Early Development at Pharvaris N.V., recently acquired 2,300 shares of the company. This insider purchase was made on June 25, 2026, at an average price of $4.73 per share, totaling $10,870.95. The transaction was not part of a pre-planned trading plan.
Insider Buying and Selling at Pharvaris N.V.
In addition to Anne Lesage's acquisition, other insider activities at Pharvaris N.V. were noted. On June 26, 2026, Chief Medical Officer Lu Peng bought 14,700 shares at $2.59 each. Meanwhile, Johannes Gerardus Schikan sold 2,400 shares on June 29, 2026, at $35.10 per share under a planned sale.
Pharvaris N.V. Stock Down 1.7%
Shares of NasdaqGS:PHVS traded near $34.01 on Tuesday. Pharvaris N.V. holds a market cap of approximately $2.38 billion. The stock has experienced a 52-week low of $16.72 and a high of $35.33. It currently has a 50-day moving average of $30.50 and a 200-day moving average of $26.70. The company shows strong liquidity with a current ratio of 11.24 and a quick ratio of 10.99, while its debt-to-equity ratio stands at 0.31.
$PHVS stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Morgan Stanley maintained its buy rating for Pharvaris N.V. with a price target of $46. Other analysts have also shown confidence in the stock, with Citizens maintaining a buy rating and setting a target of $74 on May 13, 2026. The consensus among 13 analysts is a strong buy, with a mean target price of $46.15.
About Pharvaris N.V.
Pharvaris N.V. is a biotechnology company based in Zug, Switzerland, focusing on developing treatments for rare diseases, particularly those related to bradykinin-mediated angioedema. The company is working on deucrictibant, a small molecule therapy currently in phase 3 trials, aimed at treating hereditary angioedema and other similar conditions. Pharvaris was established in 2015 and is led by CEO Berndt Axel Edvard Modig.
Bottom Line
Anne Lesage's recent purchase highlights insider confidence in Pharvaris N.V. The company's stock, trading near its 52-week high, reflects a promising outlook in the biotechnology sector. Investors often track such insider transactions for potential insights into company performance. However, it's important to remember that these trades are disclosed after the fact and may not indicate future actions.
Get Pharvaris N.V. alerts
New 13F filings, insider trades, and analyst moves on $PHVS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.